Drug Trial Radar · NCT07228390
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
128
Actual
Start
Nov 13, 2025
Primary completion
Dec 8, 2026
Study completion Jan 5, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS). HS is a disease causing long lasting painful red skin lumps. This study is seeking participants who: * have moderate or severe HS * have previously received antibiotics for HS that did not help, or could not tolerate antibiotics Participants will be randomly (like a flip of coin) assigned to receive either the study medicine or a placebo (a pill that looks like the study medicine but does not contain any medicine). The study medicine or placebo will be taken by mouth once daily at home. For the first part of the study, participants will receive a loading (starting) dose. For the next part of the study, participants will receive a maintenance (ongoing) dose. Participants will take part in the study for about 24 weeks (about 6 months). There will be about 10 study clinic visits: a screening visit, Day 1, and then every 1, 2, or 4 weeks until week 16. At each visit, participants will report on their health and have tests such as physical exams, blood and urine tests, vital signs, chest X-rays, ECGs, hearing tests, and questionnaires. Participants will record when they take the study medicine and their HS symptoms every day in an eDiary on a mobile phone. The experiences of participants receiving the study medicine will be compared to those receiving placebo to help see if the study medicine is safe and effective.
Conditions
- Hidradenitis Suppurativa
Interventions
RitlecitinibDrug
Participants will receive one oral dose once daily (QD), starting with a loading dose of ritlecitinib for 8 weeks, followed by maintenance for 8 weeks.
PlaceboDrug
Participant will receive matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in proportion of responders based on Hidradenitis Suppurativa Clinical Response achieving at least 50% reduction from baseline (Hidradenitis Suppurativa Clinical Response HiSCR50) in patients with HS treated with ritlecitinib versus placebo.Time frame: Week 16
Locations
57 sites in 6 countries. Site status is shown where the registry gives one.
Burke Pharmaceutical Research
Hot Springs, Arkansas
First OC Dermatology Research Inc
Fountain Valley, California
Northridge Clinical Trials
Northridge, California
Integrative Skin Science and Research
Sacramento, California
Wolverine Clinical Trials
Santa Ana, California
Skin Care Research
Boca Raton, Florida
Olympian Clinical Research
Largo, Florida
Ziaderm Research LLC
North Miami Beach, Florida
D&H Tamarac Research Center
Tamarac, Florida
NMC Research LLC
Tampa, Florida
USF - Carol and Frank Morsani Center for Advanced Healthcare-Clinical Research Center
Tampa, Florida
Alliance Clinical Research of Tampa
Tampa, Florida
Olympian Clinical Research
Tampa, Florida
USF Florida Hearing Clinic
Tampa, Florida
TruDerm & TruSpa
Wellington, Florida
Advanced Medical Research, PC.
Sandy Springs, Georgia
Endeavor Health
Skokie, Illinois
The Indiana Clinical Trials Center, PC
Plainfield, Indiana
Options Research Group
West Lafayette, Indiana
Essential Medical Research - Overland Park
Overland Park, Kansas
Skin and Hair Center
Overland Park, Kansas
DS Research of Kentucky
Louisville, Kentucky
Revival Research Institute, LLC
Southfield, Michigan
Revival Research Institute, LLC
Troy, Michigan
Stracskin
Portsmouth, New Hampshire
ClinOhio Research Services
Columbus, Ohio
Columbia Dermatology & Aesthetics
Columbia, South Carolina
Palmetto Clinical Trial Services - Greenville
Greenville, South Carolina
Center for Clinical Studies, LTD. LLP
Houston, Texas
Eurofins CRL
Forest, Virginia
Centre de Recherche Saint-Louis inc.
Québec, Canada
Dermatology Research Institute
Calgary, Alberta, Canada
Laser Rejuvenation Clinics Edmonton D.T. Inc
Edmonton, Alberta, Canada
Skin Physicians Dermatology
Edmonton, Alberta, Canada
CaRe Clinic
Red Deer, Alberta, Canada
Ryan Clinical Research Inc.
Newmarket, Ontario, Canada
DAR Clinical Research
Ottawa, Ontario, Canada
North York Research Inc
Toronto, Ontario, Canada
FACET Dermatology
Toronto, Ontario, Canada
Universitätsklinikum Frankfurt
Frankfurt, Germany
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.